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Background: People with chronic kidney disease (CKD) are at high-risk of polypharmacy. However, 
no previous study has investigated international prescribing patterns in this group. 
This paper aims to examine prescribing and polypharmacy patterns amongst older people with 
advanced CKD across the countries involved in the European Quality Study (EQUAL). 
Methods: The EQUAL study is an international prospective cohort study of patients ≥ 65 years of age 
with advanced CKD. Baseline demographic, clinical and medication data were analysed and reported 
descriptively. Polypharmacy was defined as ≥5 medications and hyperpolypharmacy as ≥10. 
Univariable and multivariable linear regression were used to determine associations between 
country and number of prescribed medications. Univariable and multivariable logistic regression 
were used to determine associations between country and hyperpolypharmacy.  
Results: Of the 1317 participants from 5 European countries, 91% were experiencing polypharmacy 
and 43% were experiencing hyperpolypharmacy. Cardiovascular medications were the most 
prescribed medications (mean 3.5 per person). 
There were international differences in prescribing with significantly greater hyperpolypharmacy in 
Germany (OR 2.75, 95% CI 1.73-4.37, p<0.001, reference group United Kingdom), the Netherlands 
(OR 1.91, 95% CI 1.32-2.76, p=0.001) and Italy (OR 1.57, 95% CI 1.15-2.15, p=0.004). People in Poland 
experienced the least hyperpolypharmacy (OR 0.39, 95% CI 0.17-0.87, p=0.021). 
Conclusions: Hyperpolypharmacy is common amongst older people with advanced CKD, with 
significant international differences in the number of medications prescribed. Practice variation may 
represent a lack of consensus regarding appropriate prescribing for this high-risk group, for whom 
pharmacological treatment has great potential for harm, as well as benefit.  
 









Polypharmacy rates are rising, particularly amongst older people.1 Drivers for polypharmacy in the 
general population include multimorbidity, increased use of preventative medications, and 
guidelines which focus on single diseases.2–5 Negative consequences of polypharmacy include drug-
drug interactions, adverse drug reactions, poor adherence and increased treatment burden, 
alongside greater medication costs.6–10 
Polypharmacy and inappropriate prescribing are common in people with all stages of chronic kidney 
disease (CKD), including those receiving renal replacement therapy (RRT).11–16 For people with 
advanced CKD, two key factors which influence prescribing are the high levels of comorbidity and 
the development and treatment of CKD related complications; for example, renal anaemia and renal 
bone disease.11,17 Furthermore, patients with advanced CKD are particularly vulnerable to adverse 
drug events due to altered pharmacodynamics and pharmacokinetics. 
Although polypharmacy in people with CKD has been demonstrated in a variety of countries and 
settings, no previous study has made international comparisons in prescribing.18–21 International 
differences in healthcare systems, health beliefs, disease prevalence and clinical guidelines are some 
of the factors that may influence national prescribing patterns. A better understanding of 
international prescribing approaches could inspire trans-national learning and inform further work 
to identify individual, local and national factors to encourage appropriate prescribing. 
The aim of this paper is to examine prescribing patterns and the prevalence of polypharmacy in 
older people with advanced CKD across the countries taking part in the European Quality Study 
(EQUAL). 
 
Materials and methods 
The EQUAL study is an international prospective cohort study which aims to determine the optimum 
timing of dialysis initiation for older people with advanced CKD.  Eligible participants were recruited 
from nephrology clinics in six European countries (Germany, Italy, the Netherlands, Poland, United 
Kingdom (UK) and Sweden). Inclusion criteria were age ≥65 years old and an incident estimated 
glomerular filtration rate (eGFR) ≤20ml/min/1.73m2 in the last 6 months, as estimated by the 
Modification of Diet in Renal Disease equation.22 Participants were excluded if the decrease in eGFR 
was the result of an acute event or if they had received RRT prior to study recruitment.23 Approval 
was obtained from the medical ethical committees or institutional review boards for all participating 
centres. Written informed consent was obtained for all eligible participants. The baseline data from 
the first study visit for people who were recruited from 1st March 2012 to 31st December 2017 were 
used in this study.  
Data collection 
Participants from Germany, Italy, the Netherlands, Poland and the UK were included in this analysis. 





linkage and so data were only available for a limited list of medications. The remaining countries 
collected demographic, clinical and medication data using a case report form administered in person 
by a research nurse and corroborated against their medical notes. A list of the participant’s current 
prescribed medications was recorded; ‘over the counter’ medication use and medication adherence 
were not captured. A weighted comorbidity score was calculated using the Charlson Comorbidity 
Index (CCI).24 Primary renal diagnosis was standardised using European Renal Association – European 
Dialysis and Transplant Association codes.25 In order to compare the education systems and 
qualifications in the included countries, the EQUAL investigators created standardised education 
categories. 
Number of medications, medication categories and polypharmacy 
The ‘number of medications’ was computed as a simple count of unique preparations recorded at 
the first study visit.  Medications were assigned their corresponding Anatomical-Therapeutic-
Chemical (ATC) classification codes.26 Medication categories were created based upon the first level 
of the ATC codes (for example, ‘cardiovascular system’). If a medication category was deemed low 
use it was amalgamated into an ‘other’ category.  
There is no universally accepted definition of polypharmacy. In the descriptive analysis, categories of 
polypharmacy (≥ 5 medications) and hyperpolypharmacy (≥ 10 medications) were defined. These are 
the most commonly used numerical definitions in the literature.27 Combination medications (for 
example, co-amilofruse or combination inhalers) were counted as one medication, rather than their 
separate components. 
Prescribing quality indicators 
A validated list of prescribing quality indicators (PQIs) which are specific to patients with CKD, were 
used to assess prescribing quality.28,29 The original list of 16 PQIs was shortened to an operational list 
of 10 PQIs which were appropriate for our study cohort and the available data (see appendix 1 for 
PQI selection details).  The authors of the original PQI list have previously adapted and shortened the 
list in a similar manner before applying it to data.29 
 
Statistical analyses 
Descriptive statistics were used to summarise baseline demographic characteristics of study 
participants according to country of residence. PQIs and specific medications were compared across 
countries using Chi squared and Fisher’s exact tests. Univariable and multivariable linear regression 
were used to determine the association between country of residence and number of prescribed 
medications. Univariable and multivariable logistic regression were used to determine the 
association between country of residence and hyperpolypharmacy. The multivariable linear 
regression and multivariable logistic regression analyses adjusted for variables which were identified 
as confounders30: age, educational attainment, ethnicity, sex, eGFR, primary renal diagnosis and co-
morbidities. Both the multivariable analyses used robust standard errors to account for potential 








Characteristics of the study cohort 
From a potential 1,344 EQUAL participants, 27 lacked medication data and were excluded. The 
majority of the excluded patients were from the Netherlands and Germany (n=12, 5.2% and n=9, 
6.0% respectively). Of the 1,317 remaining, 846 (64.2%) were male and the mean age was 76.5 years 
(standard deviation (SD) 6.7). The majority were white (n=1,262, 95.8%). With regards to educational 
attainment, only a minority of patients had university degrees (n=98, 7.4%). The median eGFR at the 
first study visit was 18.0mL/min/1.73m2 (inter-quartile range (IQR) 16.0-19.0). Multimorbidity was 
common; all participants had at least one comorbidity in addition to CKD (n=1,293, 24 patients had 
missing comorbidity data). The most frequent comorbidities were hypertension, diabetes mellitus 
and coronary artery disease (84.4%, 42.4% and 27.3% of people respectively). The mean body mass 
index (BMI) was 28.5kg/m2 (SD 5.4). The majority of people with available smoking data were ex-
smokers (n=558, 42.4%) and only 71 (5.4%) were current smokers, (smoking data was unavailable for 
380 people, 28.9%). Hypertensive nephropathy was the most commonly reported primary renal 
diagnosis (n=426, 32.4%).  
The demographic and clinical characteristics of the study cohort by country of residence are shown 
in table 1. The majority (68.6%) of participants were from the UK and Italy, with only 50 (3.8%) from 
Poland. Participant recruitment spanned 5 years with people from the UK, Germany and Italy 
recruited earlier in the study period than those in the Netherlands and Poland. Mean age and CCI 
were comparable across all countries.  Fewer people from Germany had a diagnosis of hypertensive 
nephropathy (17.6%) compared to those from the other countries (mean 32.4%). People recruited 
from Germany also had a lower median eGFR (16.0 mL/min/1.73m2, IQR 13.7-19.0) at their first 
study visit than those from other countries.  There was a variation in educational attainment across 
different countries with participants from the Netherlands and the UK having the highest levels of 
education.  
Prescribed medications 
The mean number of prescribed medications was 9.1 (SD 3.6, range 0.0-22.0). Ninety one percent of 
participants were experiencing polypharmacy (n=1,194), with 42.8% experiencing 
hyperpolypharmacy (n=564).   
Participants in Germany were prescribed the greatest number of medications per person (mean 
10.4, SD 3.8) and people in Poland were prescribed the fewest (mean 7.2, SD 2.8). For the purpose of 
analysis, the largest group (UK) were used as the reference group. In the multivariable analysis, 
people in Germany were prescribed 1.90 more medications than those in the UK (95% CI 1.23-2.56, 
p<0.001, table 2). People in Poland were prescribed 1.20 fewer medications than people in the UK 
(95% CI-2.15- -0.24, p=0.029, table 2).  
People who were recruited from Germany, the Netherlands and Italy were most likely to experience 
hyperpolypharmacy (OR 2.75, 95% CI 1.73-4.37, p<0.001, OR 1.91, 95% CI 1.32-2.76, p=0.001 and OR 





When the medications were categorised by ATC code, ‘cardiovascular’ were found to be the most 
prescribed group of medications in all countries (figure 2), with a mean of 3.5 cardiovascular 
medications per person (SD 1.7). Proton pump inhibitors (PPIs) were the most frequently prescribed 
‘non-cardiovascular’ medication (n=612, 46.5%). Of note, 41.7% (n=255) of patients who were 
prescribed PPIs were also prescribed aspirin. Diuretics, statins, calcium channel blockers and beta 
blockers were each prescribed to over half of all individuals (66.1%, 60.0%, 52.5% and 50.7% 
respectively, table 4). Co-prescription of multiple classes of diuretics was infrequent with 154 
patients (11.7%) prescribed 2 classes of diuretic and 6 patients (0.5%) prescribed three different 
classes. Combination medications were infrequently prescribed; formoterol and budesonide inhaler 
was the most commonly prescribed combination (n=41, 3.1%) followed by irebesartan-
hydrochlorothiazide (n=10, 0.8%). Iron and erythropoiesis stimulating agents (ESAs) were prescribed 
to approximately a quarter of the individuals (n=363, 27.6% and n= 334, 25.4%, respectively). 
Vitamin D supplementation in either nutritional or activated form was common (n=312, 23.7% and 
n=521, 39.6%, respectively). Around a quarter of participants were prescribed sodium bicarbonate 
(n=327, 24.8%).  
Prescriptions of different medication groups varied between countries (figure 2). Recruits from 
Poland were prescribed fewer medications from the ‘Alimentary tract and metabolism’ ATC 
category. In particular, fewer PPIs, activated and nutritional vitamin D supplements (10.0%, 8.0% and 
6.0% respectively) were prescribed to Polish recruits, compared with others (table 4). German 
participants had the highest number of prescriptions for loop diuretics, angiotensin converting 
enzyme (ACE) inhibitors, beta blockers and sodium bicarbonate compared to people from the other 
countries. Tests for proportions indicate that there are differences in prescribing of all but two of the 
20 most prescribed agents (tamsulosin and clopidogrel, table 4). 
Prescribing quality indicators 
The proportion of people fulfilling PQIs for potentially appropriate and inappropriate prescribing are 
shown in table 5 and figure 3.  PQIs which examined potentially appropriate prescribing showed that 
almost all people (n=1243, 97.8%) who might benefit from antihypertensives were prescribed one. 
However, only half of people (n=176, 48.8%) who might benefit from phosphate binders were 
prescribed one; the Netherlands had the highest proportion of phosphate binder prescriptions to 
those who might benefit (n= 52, 75.4%, p < 0.001). Only a small number of individuals who were 
prescribed phosphate binders had calcium levels which were classed as too low or too high.  Out of 
those with low calcium levels, the majority were receiving a calcium containing binder (n=15, 80%). 
Out of those with high calcium levels, roughly half were receiving a non-calcium containing binder 
(n=6, 54.5%). 
With regard to potentially inappropriate prescribing, there were few prescriptions for dual renin-
angiotensin system (RAS) blockade or non-steroidal anti-inflammatory drugs (NSAIDs) (n=24, 1.8% 
and n=14, 1.1%, respectively). People from the UK had the greatest number of NSAID prescriptions 
compared to those from the other countries (n=11, 2.2%, p=0.010). A minority of people were 
prescribed the combination of RAS inhibitors, NSAIDs and diuretics (n=8, 0.6%). Out of those with 
diabetes, 14 people were prescribed metformin (2.5%).  Out of those with high calcium levels, 22 
people (41.5%) were prescribed activated vitamin D, with the greatest proportion of these 





levels ≥7.5 mmol/L 66 people (14.3%) were prescribed ESAs, with a greater proportion of these 
people residing in Germany and Italy (n= 11, 21.2% and n=29, 21.6%, respectively, p=0.006).   
 
Discussion 
In this international comparison of prescribing in older people with advanced CKD, 91% of 
individuals experienced polypharmacy and 43% experienced hyperpolypharmacy. The prevalence of 
polypharmacy is over three-times higher than that observed in people of a similar age in the general 
population in England (28% in patients aged 60 years or above), but consistent with that reported in 
the French CKD-REIN cohort (87% for patients with CKD stage 4 or 5).2,12 At a national level, the 
mean number of medications prescribed to people aged 65 years and over with an incident eGFR of 
less than 20mL/min/1.73m2 ranged between 7.2 in Poland to 10.4 in Germany, and this three-
medication gap between the highest and lowest-prescribing nations persisted after adjustment for 
potential clinical and socio-demographic confounders.  
Prescribing patterns in the general population are known to vary by nation; for example, UK 
antihypertensive drug consumption has been reported to be two-thirds that of patients in 
Germany.31  International variation in prescribing for people with CKD may largely reflect country-
level factors, independent from CKD-specific influences. Whether the between-country differences 
are driven chiefly by prescription of medications overall, or by greater and lesser use of particular 
drugs or drug classes is difficult to untangle. However, the high prevalence of polypharmacy and 
hyperpolypharmacy, and the marked variation in hyperpolypharmacy between countries point 
towards comprehensive differences in prescribing approaches. The factors driving international 
variation may operate through patient and clinician behaviours, or through healthcare systems. 
Patient expectations and shared decision making are linked to health and cultural beliefs and are 
likely to differ with country of residence.32 Cultural attitudes towards acceptance of multiple 
medications may be driven, for example, by preferences for preventative care. Clinician behaviours 
may also differ between nations and influence the likelihood of recommending regimens with larger 
numbers of medications. Drivers may include tendencies for clinicians to prescribe an additional 
medication, compared with recommending a lifestyle or other non-medicinal intervention. It is 
possible that there are national differences in how comfortable clinicians and patients are to share 
decisions regarding prescribing, whereby the number of medications prescribed may be more 
person-centred in some nations than others. The five included countries have diverse organisational 
and funding arrangements for health care provision and whilst they share similar goals, there are 
likely to be nuances which influence prescribing patterns, such as prescription charges, implicit 
rationing or quality assurance measures designed to limit polypharmacy.33–36 The interplay and 
communication between specialists and primary care may also differ at a national level; the overall 
responsibility for medication review and reconciliation may fall to one of these clinicians or be split 
between multiple clinicians.  
Prescribing for patients with advanced CKD is particularly complex due to multimorbidity, altered 
drug kinetics and clearance, and imprecise estimates of residual renal function. On account of the 
need for individualised prescribing, it is impossible to remark conclusively on the appropriateness of 





highlighted areas of possible good and bad practice; however some of these prescriptions may be 
the result of individual patient preference or specific circumstances where guidelines may not be 
applicable. Nevertheless, variation in the numbers and nature of medicines prescribed suggests a 
lack of consensus as to what the ‘right’ level of prescribing is for this group.  
Cardiovascular drugs were the most prescribed group in this cohort, with each person prescribed an 
average of 3.5 cardiovascular medications. Adult prescribing data from 40 general practices in 
Scotland demonstrated that cardiovascular medications were the most prescribed group of 
medications in the general population as well, with 13.5% of all adult patients prescribed three or 
more cardiovascular drugs.38 The high use of cardiovascular medications in our study is likely to 
reflect the increased risk of cardiovascular events and high prevalence of cardiovascular 
comorbidities amongst individuals with CKD. Two highly prevalent drugs, PPIs (46.5% of recruits) and 
statins (60.0%), have both been previously identified as targets for de-prescribing interventions.39–43 
It is noteworthy that, with the exception of PPIs, few of the most commonly prescribed medications 
could be expected to provide symptomatic benefit, with notably low levels of analgesic prescription. 
Chronic pain is a common symptom for patients with advanced CKD and is often undertreated.44,45 It 
is possible, even against the backdrop of polypharmacy that there is both overtreatment and under 
treatment at play. 
The greatest strength of this study is the use of a multinational cohort of individuals who met strict 
inclusion criteria for age and renal function. However, only a limited number of countries were 
included in this international comparison with just 50 patients from Poland. Strictly-applied eligibility 
criteria will have helped to ensure a homogeneous group of patients. Nevertheless, older patients 
with eGFR ≤20mL/min/1.73m2 receiving nephrology care may differ between countries in many 
ways, including who is eligible for a nephrology referral, whether the referral can be made directly or 
through a primary care provider, at what point referral is made, and what care is received before 
that point. The variances in some baseline clinical and demographic characteristics between nations, 
such as the lower median eGFR observed in Germany, may indicate such differences were present. 
The high levels of white ethnicity, even though advanced CKD is more common in non-white people, 
may reflect bias in terms of included centres (from areas with smaller black and minority ethnic 
populations) or in terms of recruited individuals.46 This could influence the generalisability of the 
findings, especially if there is an association between ethnicity and prescribing patterns. Indeed, the 
study focuses on older patients with advanced CKD and so the findings may not be applicable to 
younger patients or those with less severe stages of CKD. 
The rigorous and protocolised approach to prospective data collection means that the medication 
data can be used with confidence. Unfortunately, this approach did not allow capture of ‘over-the-
counter’ medications and so may have led to an underestimate of total medication use. In addition, 
the cross-sectional design of the study prevents any comment on medication changes over time and 
may have led to short term medications being underrepresented, which may have contributed to 
lower documentation of analgesics and other agents with intended symptomatic benefits. The lack 
of comprehensive proteinuria data led to four PQIs from the original list being excluded from our 
operational PQI list. Five of the PQIs required laboratory measures and the results of these tests may 
not have been available until after the baseline study visit. Therefore changes to the prescriptions 
may have been made once the results were known, which would not have been captured due to the 





reflect good or bad prescribing practice. Furthermore, medications were recorded by name, but not 
dosing regimen, so we were unable to calculate number of tablets taken, dosing frequencies or drug 
doses prescribed. We were unable to comment on indications for medications or patient adherence 
to medication. 
Whilst in general, rates of polypharmacy are rising,1 even though study recruitment spanned five 
years the highest prevalence of polypharmacy was observed in patients from Germany, who were 
recruited earlier in the study period. The lowest prevalence of polypharmacy was observed in 
patients from Poland, who were recruited later. Therefore rising polypharmacy rates during study 
recruitment are likely to have led to under-estimation of the differences demonstrated.  
 
Conclusion  
This study has demonstrated both a high prevalence of polypharmacy and hyperpolypharmacy and 
also significant international differences in the number of medications prescribed to older patients 
with advanced CKD. Such variation in routine clinical prescribing suggests a lack of international 
consensus regarding what is ‘appropriate’ prescribing for older people with advanced CKD, amongst 
whom pharmacological treatment has great potential for harm as well as benefit. Further work is 
needed to identify the key factors that are driving these international differences in prescribing, to 
explore how prescribing patterns change over time and to ascertain whether and when 
deprescribing occurs, and to determine how these changes relate to treatment burden, patient 
outcomes and quality of life. 
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Table 1. Demographic and clinical characteristics of the study cohort 
 Germany Italy Netherlands Poland UK Total 
Study 
participants 
n (% of total cohort) 142 (10.8) 406 (30.8) 221 (16.8) 50 (3.8) 498 (37.8) 1317 
(100.0) 
Sex Male, n (%) 82 (57.8) 267 (65.8) 153 (69.2) 35 (70.0) 309 (62.1) 846 (64.2) 
Age  Mean years (SD) 76.9 (6.4) 77.1 (6.8) 75.5 (6.4) 76.1 (7.5) 76.6 (6.8) 76.5 (6.7) 
Ethnicity White, n (%) 142 (100.0) 403 (99.3) 208 (94.1) 50 (100.0) 459 (92.2) 1262 (95.8) 
Primary renal 
diagnosis 
Glomerular, n (%) 17 (12.0) 21 (5.2) 21 (9.5) 6 (12.0) 40 (8.0) 105 (8.0) 
Tubulo-interstitial, n (%) 9 (6.3) 31 (7.6) 14 (6.3) 3 (6.0) 48 (9.6) 105 (8.0) 
Systemic, n (%) 3 (2.1) 3 (0.7) 4 (1.8) 1 (2.0) 13 (2.6) 24 (1.8) 
Diabetes, n (%) 32 (22.5) 90 (22.2) 33 (14.9) 9 (18.0) 96 (19.3) 260 (19.7) 
Hypertension, n (%) 25 (17.6) 150 (37.0) 89 (40.3) 18 (36.0) 144 (28.9) 426 (32.4) 
Familial, n (%) 5 (3.5) 9 (2.2) 5 (2.3) 6 (12.0) 11 (2.2) 36 (2.7) 
Miscellaneous, n (%) 4 (2.8) 12 (3.0) 8 (3.6) 1 (2.0) 27 (5.4) 52 (4.0) 
Unknown, n (%) 20 (14.1) 74 (18.2) 24 (10.9) 4 (8.0) 109 (21.9) 231 (17.5) 
Missing, n (%) 27 (19.0) 16 (3.9) 23 (10.4) 2 (4.0) 10 (2.0) 78 (5.9) 
eGFR Median eGFR 















Mean CCI (SD) 7.2 (1.7) 7.3 (1.8) 7.1 (1.8) 7.3 (2.3) 7.0 (1.8) 7.1 (1.8) 
Comorbidities Diabetes, n (%) 78 (54.9) 185 (45.6) 85 (38.5) 17 (34.0) 193 (38.8) 558 (42.4) 
Hypertension, n (%) 124 (87.3) 378 (93.1) 178 (80.5) 48 (96.0) 384 (77.1) 1112 (84.4) 
History of major 
vascular event, n (%) 
53 (37.3) 158 (38.9) 102 (46.2) 28 (56.0) 152 (30.5) 493 (37.4) 
Malignancy, n (%) 20 (14.1) 74 (18.2) 57 (25.8) 9 (18.0) 110 (22.1) 270 (20.5) 
Missing, n (%) 3 (2.1) 3 (0.7) 7 (3.2) 0 11 (2.2) 24 (1.8) 
Educational 
attainment 
No education, n (%) 0  28 (6.9) 1 (0.5) 0 0 29 (2.2) 
Primary school, n (%) 9 (6.3) 112 (27.6) 29 (13.1) 10 (20.0) 158 (31.7) 318 (24.2) 
Secondary school or 
vocational course, n (%) 
96 (67.6) 120 (29.6) 86 (38.9) 27 (54.0) 142 (28.5) 471 (35.8) 
University degree, n (%) 6 (4.2) 20 (4.9) 36 (16.3) 0 36 (7.2) 98 (7.4) 
Other, n (%) 13 (9.2) 0 7 (3.2) 0 0 20 (1.5) 
Missing, n (%) 18 (12.7) 126 (31.0) 62 (28.1) 13 (26.0) 162 (32.5) 381 (28.9) 
BMI Mean kg/m2 (SD)  30.1 (5.6) 27.4 (5.0) 28.2 (4.5) 28.0 (5.3) 29.2 (5.6) 28.5 (5.4) 
Medications Mean number of 
medications (SD) 
10.4 (3.8) 9.2 (3.0) 9.6 (3.8) 7.2 (2.8) 8.6 (3.7) 9.1 (3.6) 
Polypharmacy, n (%) 134 (94.4) 382 (94.1) 203 (91.9) 41 (82.0) 434 (87.2) 1194 (90.7) 
Hyperpolypharmacy, n 
(%) 
82 (57.8) 183 (45.1) 110 (49.8) 9 (18.0) 180 (36.1) 564 (42.8) 
Abbreviations: SD standard deviation; eGFR estimated glomerular filtration rate; IQR interquartile range; CCI Charlson Co-
morbidity Index; BMI body mass index. Definitions: history of major vascular event - previous stroke, myocardial infarction, 

















Table 2. International comparison of number of medications  
 Univariable linear regression Multivariable linear regression*  
Country (n) β  P value 95% CI β  P value 95% CI 
UK (498) 0.00 Reference group 0.00 Reference group 
Germany (142) 1.87 <0.001 1.21    -   2.52 1.90 <0.001 1.23    -  2.56 
Italy (406) 0.51 0.029 0.05    -   0.97 0.47 0.038 -0.03   -  0.92 
Netherlands (221) 1.00 <0.001 0.44    -   1.55 1.09 <0.001 0.56    -  1.62 
Poland (50) -1.41 0.007 -2.43  -  -0.39 -1.20 0.014 -2.15   -  -0.24 
*Adjusted for age, ethnicity, sex, educational attainment, co-morbidities (hypertension, diabetes, cerebrovascular disease, 
myocardial infarction, cardiac arrhythmias, lung disease and psychiatric disorders), eGFR and primary renal diagnosis.  
Table 3. International comparison of hyperpolypharmacy  
 Univariable logistic regression Multivariable logistic regression* 
Country (n) OR P value 95% CI OR P value 95% CI 
UK (498) 1.00 Reference group 1.00 Reference group 
Germany (142) 2.41 <0.001 1.65    -   3.53 2.75 <0.001 1.73    -  4.37 
Italy (406) 1.45 0.007 1.11    -   1.89 1.57 0.004 1.15    -  2.15 
Netherlands (221) 1.75 0.001 1.27    -   2.41 1.91 0.001 1.32    -  2.76 
Poland (50) 0.39 0.013 0.18    -  0.82 0.39 0.021 0.17    -  0.87 
*Adjusted for age, ethnicity, sex, educational attainment, co-morbidities (hypertension, diabetes, cerebrovascular disease, 
myocardial infarction, cardiac arrhythmias, lung disease and psychiatric disorders), eGFR and primary renal diagnosis. 



































Diuretics – any 117 (82.4) 310 (76.4) 128 (57.9) 36 (72.0) 280 (56.2) 871 (66.1)  <0.001 
       Loop diuretics 112 (78.9) 290 (71.4) 95 (43.0) 34 (68.0) 239 (48.0) 770 (58.5) - 
      Thiazide diuretics 6 (4.2) 63 (15.5) 23 (10.4) 1 (2.0) 35 (7.0) 128 (9.7) - 
      Aldosterone antagonists 15 (10.6) 20 (4.9) 24 (10.9) 3 (6.0) 24 (4.8) 86 (6.5) - 
      Other potassium sparing agent 1 (0.7) 0 0 0 3 (0.6) 4 (0.3) - 
      Other 20 (14.1) 3 (0.7) 9 (4.1) 1 (2.0) 16 (3.2) 49 (3.7) - 
Statins 82 (57.7) 201 (49.5) 146 (66.1) 32 (64.0) 329 (66.1) 790 (60.0) <0.001 
Calcium channel blockers 78 (54.9) 205 (50.5) 116 (53.5) 37 (74.0) 256 (51.4) 692 (52.5) 0.03 
Beta blockers 107 (75.4) 176 (43.4) 134 (60.6) 35 (70.0) 216 (43.4) 668 (50.7) <0.001 
Proton pump inhibitors 47 (33.1) 253 (62.3) 108 (48.9) 5 (10.0) 199 (40.0) 612 (46.5) <0.001 
Activated vitamin D 76 (53.5) 219 (53.9) 104 (47.1) 4 (8.0) 118 (23.7) 521 (39.6) <0.001 
Aspirin 63 (44.4) 163 (40.1) 49 (22.2) 15 (30.0) 184 (36.9) 474 (36.0) <0.001 
Allopurinol 57 (40.1) 219 (53.9) 50 (22.6) 22 (44.0) 89 (17.9) 437 (33.2) <0.001 
Insulin 66 (46.5) 147 (36.2) 76 (34.4) 10 (20.0) 110 (22.1) 409 (31.1) <0.001 
Iron (intravenous or oral) 26 (18.3) 140 (34.5) 40 (18.1) 14 (28.0) 143 (28.7) 363 (27.6) <0.001 
Erythropoiesis stimulating agents 45 (31.7) 161 (39.7) 55 (24.9) 0 73 (14.7) 334 (25.4) <0.001 
Sodium bicarbonate 71 (50.0) 102 (25.1) 37 (16.7) 2 (4.0) 115 (23.1) 327 (24.8) <0.001 
Angiotensin receptor II blockers 39 (27.5) 105 (25.9) 76 (34.4) 2 (4.0) 105 (21.1) 327 (24.8) <0.001 
Nutritional vitamin D 75 (52.8) 82 (20.2) 122 (55.2) 3 (6.0) 30 (6.0) 312 (23.7) <0.001 
ACE inhibitors 56 (39.4) 41 (10.1) 61 (27.6) 9 (18.0) 117 (23.5) 284 (21.6) <0.001 
Alpha blockers (excluding 
tamsulosin) 
14 (9.9) 81 (20.0) 22 (10.0) 16 (32.0) 146 (29.3) 
279 (21.2) 
<0.001 
Levothyroxine 29 (20.4) 25 (6.2) 20 (9.0) 6 (12.0) 52 (10.4) 132 (10.0) <0.001 
Clopidogrel 10 (7.0) 35 (8.6) 21 (9.5) 4 (8.0) 54 (10.8) 124 (9.4) 0.636 
Tamsulosin 13 (9.2) 33 (8.1) 24 (10.9) 9 (18.0) 44 (8.8) 123 (9.3) 0.207 
Warfarin 1 (0.7) 34 (8.4) 0 1 (2.0) 74 (14.9) 110 (8.4) <0.001 
*In addition, 124 people had a medication recorded which was classified as ‘unknown’.  







Table 5. Prescribing quality indicators 
PQI n, (%)* Germany Italy Netherlands Poland UK P value 
Potentially appropriate prescribing 
1. 1. Patients with hypertension that are 
prescribed antihypertensives unless 













2. 2. Patients with an elevated phosphate level 













3. 3. Patients treated with phosphate binders 
and with an elevated calcium level 
(>2.54 mmol/L) that are prescribed a non-








4. 4. Patients treated with phosphate binders 
and with a low calcium level (<2.10 mmol/L) 











Potentially inappropriate prescribing 
5. Patients treated with RAS inhibitors that 
are prescribed at least two RAS inhibitors 











6. 6. Patients with an elevated calcium level 











7. 7. Patients with a normal haemoglobin level 




























10. 10. Patients that are prescribed a 









*Number and percentage of patients who meet the indicator outcome out of all of those who meet the indicator 
criteria. Data were missing for the following PQIs: PQI1-3 patients, PQI2-70 patients, PQI3 and PQI4-43 patients, 
PQI6-344 patients, PQI7-22 patients, PQI9-28 patients. Data were complete for PQI5, PQI8 and PQI10. 
Abbreviations: RAS – Renin-angiotensin system; NSAID Non steroidal anti-inflammatory drugs; ESA Erythropoiesis 
stimulating agents.  
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